Navigation Links
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Date:3/3/2009

actor receptor inhibitors like Erbitux(R) and Tarceva(R). The Company has additional pipeline opportunities that, like Marqibo, improve delivery and enhance the therapeutic index of well characterized, proven chemotherapies. Further information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,'' ``expects,'' ``plans,'' ``believes,'' ``intends,'' and similar words or phrases. These forward-looking statements include without limitation, statements regarding the expected benefits Marqibo may have for patients with relapsed ALL, expected benefits of Marqibo versus standard vincristine, potential dosing regimens, the timing, progress and anticipated results of the clinical development, regulatory processes and rates of patient enrollment of the rALLy trial, and the expected safety profile of Marqibo. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there is no assurance that Hana will have sufficient capital to complete the development of Marqibo, that the safety profile of Marqibo observed to date will be predictive of future results, that the results of the rALLy trial to date will be predictive of future results, that the rALLy trial will meet its study objectives, that Hana's development efforts relating to Marqibo will be successful, that Hana will be able to obtain
'/>"/>

SOURCE Hana Biosciences
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
2. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
3. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
4. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
5. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
10. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  MedVantx, Inc., the company that has pioneered ... today the Company has completed a major expansion of ... products and the upgrade of its systems to offer ... its specialty home delivery pharmacy in Sioux ... manufacturers, physicians, health systems and payors novel distribution services, ...
(Date:5/23/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") announced today ... Threshold from 90 percent to 50 percent of Maximum ... with the terms of the Revised Offer Document issued ... Under the terms of the Increased Offer, Royalty Pharma ... ) for $12.50 per share in cash. The Increased ...
(Date:5/23/2013)... May 23, 2013  PAREXEL International Corporation (NASDAQ: ... presenting at the Jefferies Healthcare Conference in New York.  ... and Chief Financial Officer, will be making a presentation ... on Monday, June 3, 2013. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10PAREXEL International To Present At Jefferies Healthcare Conference 2
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... for life science companies, today announced that Kevin Hrusovsky, President ... BioConference Live event, which was held on October 26, and ... Forum on October 27 held at Harvard Medical School. ...
... Conn., Nov. 7, 2011 Boehringer Ingelheim Pharmaceuticals, Inc. ... a Phase 2b study, SOUND-C2, that showed the combination ... compounds – the protease inhibitor BI 201335 and the ... successful in reducing viral load below the lower limit ...
Cached Medicine Technology:Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 3Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 4Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 5
(Date:5/23/2013)... Mayo Clinic researchers have used next generation genomic analysis ... cancer tumors have similar genetic origins, which may help ... in the journal Cancer Research . , "This ... next generation sequencing in adjacent Gleason patterns in the ... in pathology," says ,John Cheville, M.D., Mayo Clinic pathologist ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
(Date:5/23/2013)... Click here to read the full ... increasingly seeing their success develop through merger and ... according to new research carried out by MaRS , ... has compiled its research into a series of articles ... research have shown the general trend that the success ...
(Date:5/23/2013)... Cheap Concert Tickets announces that Paul McCartney will ... North America. This well known ticket website has slashed ... help McCartney fans see Sir Paul live in concert. ... is also offering the customer appreciation code SAVE for additional ... she is also a huge McCartney fan and plans to ...
(Date:5/23/2013)... (HealthDay News) -- Symptoms of borderline personality disorder ... diagnosis and treatment. But researchers in Canada say ... unique to borderline personality disorder: a tendency to ... "They have difficulty processing facial emotions and will ... said Anthony Ruocco, a clinical neuropsychologist and assistant ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3
... states that post-menopausal women who cut their fat intake and ... grains tend to lose weight. // , ,The study ... gain and increasing of obesity rates. ,The results ... a low-fat diet without any weight-loss goals. In the first ...
... scientists reports that 'mad cow'-like diseases have not been a ... that are known to be associated with disease transmission.// ... Genome Research, Prof. Jaume Bertranpetit at the Universitat Pompeu Fabra ... to show that balancing selection associated with cannibalism has not ...
... Qiang at the National Health Conference has urged the health ... poor and needy instead of spending lot of funds on ... authorities not to be partial in offering health care to ... freezing funds for hospital expansion, infrastructure development as it is ...
... A recent study reported in the American Journal of ... of attempting suicide but rather decrease the suicide risk. ... antidepressant drugs should be closely monitored to find their ... cause adverse conditions. ,The researchers ...
... now that Vitamin D supplementation helps women but in a ... women could lead to long-lasting reduction in osteoporotic fractures in ... shown that children whose mothers were lacking in vitamin D ... ,It is a common sight and medical fact that Vitamin ...
... was always profiled as a disease of the Neurons ... finger on the participation// of Astrocytes in regulating blood ... and Alzheimer’s. ,According to Neuroscientist, Dr. Maiken ... path-breaking research signals the potential contribution of Astrocytes (Star ...
Cached Medicine News:Health News:New Study Questions Cannibalism As A Worldwide Selective Force 2
PG Magnum Ring Curettes, total length 12.6" (32 cm), handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm), dual-coned, precision sharpened rings....
Karlin XL Magnum Cup Curettes, extra long (XL) curettes, black handles, lightweight, length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Caspar Curette, 250 mm, 10"....
Medicine Products: